Logo

Insights+: EMA Marketing Authorization of New Drugs in March 2024

Share this

Insights+: EMA Marketing Authorization of New Drugs in March 2024

Shots: 

  • The EC approved 1 Biologic and 11 New Chemical Entities in March 2024, leading to treatments for patients and advances in the healthcare industry 

  • In March 2024, the major highlighted drugs were Novartis’ Fabhalta to treat PNH and UCB’s Bimzelx for the treatment of Adults with Moderate to Severe Hidradenitis Suppurativa 

  • PharmaShots has compiled a list of 6 drugs that were approved or have been granted positive opinion by the EC or EMA’s CHMP, respectively 

 

 

 

1. Novo Nordisk’s Awiqli Receives the CHMP’s Positive Opinion for the Treatment of Diabetes  

Product Name: Awiqli 

Active ingredient: Insulin icodec 

Company: Novo Nordisk 

Date: Mar 21, 2024 

Disease: Diabetes 

Shots: 

  • Novo Nordisk’s Awiqli (QW basal insulin icodec) has received CHMP’s positive opinion and recommending it for the final approval which is anticipated in next ~67days/ ~2mos 

  • The opinion was supported by the six P-IIIa (ONWARDS) study assessing the safety & efficacy of Awiqli in type 1 & type 2 diabetes adults (n= >4,000) incl. Real-world analysis 

  • The study showed superior blood sugar reduction (by HbA1c) & Time in Range (time spent in RBS range) among T2D patients. Awiqli reduced HbA1c, but had a higher hypoglycemia rate  

 

2. Outlook Therapeutics’ Lytenava Gains the CHMP’s Positive Opinion for the Treatment of Wet AMD 

Product Name: Lytenava 

Active ingredient: Bevacizumab-vikg 

Company: Outlook Therapeutics 

Date: Mar 22, 2024 

Disease: Wet Age-related Macular Degeneration 

Shots: 

  • Outlook’s Lytenava has received CHMP’s positive opinion to treat Wet AMD. If approved Lytenava expected to gain 10 yrs of market exclusivity in EU 

  • The opinion was supported by 3 wet AMD clinical programs (NORSE ONE, NORSE TWO & NORSE THREE) assessing ONS-5010 along with retrospective bibliographic literature  

  • Lytenava, an ophthalmic formulation of bevacizumab, is being developed as an intravitreal injection for treating wet AMD and other retinal diseases. It is an ophthalmic formulation of existing bevacizumab which has been off label used in wAMD globally 

 

3. Novartis Reports the CHMP’s Positive Opinion for Fabhalta (iptacopan) to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH) 

Product Name: Fabhalta 

Active ingredient: Iptacopan 

Company: Novartis 

Date: Mar 22, 2024 

Disease: Paroxysmal Nocturnal Hemoglobinuria 

Shots: 

  • The opinion was based on the P-III (APPLY-PNH) & (APPOINT-PNH) trials of Fabhalta (200mg, oral, BID) in PNH patients with residual anemia who switched from Anti-C5 and complement inhibitor naïve (incl. anti-C5 therapies) respectively for 24wks. 

  • In the APPLY-PNH study, 82.3% vs 2.0% had a ≥2 g/dL increase in Hb levels without transfusions while in APPOINT-PNH, 92.2% of complement inhibitor-naïve Fabhalta patients reached the same 

  • The transfusion avoidance rate of 94.8% vs 25.9% was observed in APPLY-PNH study. Fabhalta controlled IVH with mean LDH levels <1.5 x upper limit of normal and patients experienced fatigue improvements based on FACIT-F scores 

 

4. UCB’s Bimzelx Receives CHMP’s Positive Opinion to Treat Moderate to Severe Hidradenitis Suppurativa 

Product Name: Bimzelx 

Active ingredient: Bimekizumab 

Company: UCB 

Date: Mar 22, 2024 

Disease: Moderate to Severe Hidradenitis Suppurativa 

Shots: 

  • The recommendation was supported by the P-III studies (BE HEARD I and BE HEARD II) assessing the safety and efficacy of Bimzelx 1014 patients with PsA evaluating bimekizumab vs. PBO at week 16 

  • Both trials met their 1EPs & 2EPs measured by HiSCR50 and HiSCR75 respectively at wk. 16. Clinical responses were sustained up to 48wk. in (BE HEARD I and BE HEARD II) trial 

  • For its final decision, the EC will refer to bimekizumab's positive opinion grant by the CHMP on moderate to severe HS. The marketing authorization would apply to all the EU member states and countries of the EEA 

 

5. Norgine’s NPJ5008 (Dantrolene sodium hemiheptahydrate) Receives CHMP’s Positive Opinion for the Treatment of Malignant Hyperthermia 

Product Name: NPJ5008 

Active ingredient: Dantrolene sodium hemiheptahydrate 

Company: Norgine 

Date: Mar 22, 2024 

Disease: Malignant Hyperthermia 

Shots: 

  • Norgine received a positive CHMP opinion for NPJ5008 (Dantrolene sodium hemiheptahydrate) for the treatment of Malignant Hyperthermia 

  • With NPJ5008, dantrolene is prepared and administered quickly using novel formulation vs. Dantrolene IV (dantrolene sodium). NPJ5008 (IV) contains 120 mg of dantrolene in each vial and is reconstituted in 20 mL of water 

  • For its final decision, the EC will refer to NPJ5008's positive opinion grant by the CHMP. NPJ5008’s UK (MHRA) & Switzerland (Swiss Medic) submission is ongoing 

 

6. Pfizer’s Emblaveo (aztreonam-avibactam) Receives Positive CHMP Opinion for the Treatment of Patients with Multidrug-Resistant Infections 

Product Name: Emblaveo 

Active ingredient: Aztreonam-avibactam 

Company: Pfizer 

Date: Mar 22, 2024 

Disease: Adult patients with cIAI, HAP incl. VAP, and cUTI, incl. pyelonephritis. 

Shots: 

  • Pfizer’s Emblaveo has received a positive CHMP opinion for the treatment of patients with cIAI, HAP (incl. VAP), and cUTI (incl. Pyelonephritis).  

  • The MAA was supported by results from the P-III study comprising the REVISIT and ASSEMBLE studies evaluating the efficacy, safety, and tolerability of Emblaveo in treating serious bacterial infections due to Gram-negative bacteria (incl. MBL-producing multidrug-resistant pathogens for which there are limited or no treatment options) 

  • AbbVie and Pfizer jointly developing Emblaveo, where Pfizer holds the global rights to commercialize Emblaveo outside of the U.S. and Canada and the development was also funded by US DoHHS. 

Note: 

According to the EMA’s March 2024 approval list, Neuraxpharm Pharmaceuticals’ Dimethyl fumarate Neuraxpharm, Celltrion Healthcare’s Omlyclo, Les Laboratoires Servier’s Onivyde pegylated liposomal, Accord Healthcare’s Dimethyl fumarate Accord, BrePco Biopharma’s Neoatricon, and Mylan’s Dimethyl fumarate Mylan was also approved; however, no PR was available 

Related Post: Insights+: EMA Marketing Authorization of New Drugs in February 2024 


Dipanshu Dixit

A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions